Lari­mar Ther­a­peu­tics shares key bio­mark­er da­ta, aims for ac­cel­er­at­ed ap­proval for Friedre­ich’s atax­ia drug

Lari­mar Ther­a­peu­tics an­nounced Mon­day that its Friedre­ich’s atax­ia treat­ment in­creased me­di­an lev­els of a key pro­tein called fratax­in in a mid-stage study.

The biotech is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER